Radiofrequency treatment for genitourinary syndrome of menopause (GSM) in female breast cancer patients who have undergone tamoxifen therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260208001

Enrollment

Registered

2026-02-08

Start date

2025-10-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary syndrome of the menopause Breast Cancer patients underwent Tamoxifen therapy GSM Menopause Tamoxifen Breast cancer

Interventions

Breast cancer patient underwent Tamoxifen with GSM symptoms

Treatment

Patient with GSM

Eligibility

Sex/Gender

Female

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Female age 35-70 years old 2. Breast cancer patient treated with Tamoxifen at least one year 3. Have GSM symptoms

Exclusion criteria

Exclusion criteria: 1. Active genital infection 2. HIV infection 3. Patient underwent pelvic reconstructive surgery 4. Current user of other hormonal treatment for GSM

Design outcomes

Primary

Measure	Time frame
Vaginal Health Index (VHI) 6 weeks after the intervention Paired T-Test	—

Secondary

Measure	Time frame
Side effect or adverse event during the intervention and 6 weeks after the intervention Patient reported outcome using a questionnaire interview	—

Countries

Thailand

Contacts

Public ContactNaphat Dansakulcharoen

Department of obstetrics and gynecology, Faculty of medicine, Chulalongkorn university

naphatdarn@docchula.com6622564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026